Register a trial

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05971602




Registration number
NCT05971602
Ethics application status
Date submitted
14/06/2023
Date registered
2/08/2023

Titles & IDs
Public title
Efficacy and Safety Evaluation of Two to Four Months of Treatment With the Combination Regimens of DBOS and PBOS in Adults With Pulmonary Tuberculosis
Scientific title
A Phase 2b/c, Multi-Arm, 2-Stage, Duration Randomized Trial of the Efficacy and Safety of Two to Four Months Treatment With Regimens Containing Bedaquiline, OPC-167832, and Sutezolid, Plus Either Pretomanid or Delamanid, in Adults With Pulmonary Tuberculosis
Secondary ID [1] 0 0
Gates MRI-TBD06-201
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Pulmonary Tuberculosis 0 0
Condition category
Condition code
Infection 0 0 0 0
Other infectious diseases
Infection 0 0 0 0
Studies of infection and infectious agents
Respiratory 0 0 0 0
Other respiratory disorders / diseases

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Delamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS)
Treatment: Drugs - Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS)
Treatment: Drugs - Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE)
Treatment: Drugs - Pretomanid or Delamanid, Bedaquiline, OPC-167832, and Sutezolid (XBOS)
Treatment: Drugs - Isoniazid and Rifampicin (HR)

Experimental: Stage 1: Arm 1: DS-TB Participants receiving DBOS for 4 months (17 Weeks) -

Experimental: Stage 1: Arm 2: DS-TB Participants receiving PBOS for 4 months (17 Weeks) -

Experimental: Stage 1: Arm 3: DS-TB Participants receiving 2HRZE/4HR for 6 months (26 weeks) - Isoniazid (H), Rifampicin (R), Pyrazinamide (Z), Ethambutol (E) - refers to standard regimen of 8 weeks of HRZE followed by 18 weeks of HR (2HRZE/4HR)

Experimental: Stage 2: Arm 1: DS-TB Participants receiving XBOS for 2 months (9 Weeks) - Pretomanid or Delamanid, Bedaquiline, OPC-167832, and Sutezolid (Regimen from Stage 1 that advances to Stage 2 \[XBOS\])

Experimental: Stage 2: Arm 2: DS-TB Participants receiving XBOS for 2.5 months (11 Weeks) -

Experimental: Stage 2: Arm 3: DS-TB Participants receiving XBOS for 3 months (13 Weeks) -

Experimental: Stage 2: Arm 4: DS-TB Participants receiving XBOS for 3.5 months (15 Weeks) -

Experimental: Stage 2: Arm 5: DS-TB Participants receiving XBOS for 4 months (17 Weeks) -

Experimental: Stage 2: Arm 6: DS-TB Participants receiving 2HRZE/4HR for 6 months (26 Weeks) -

Experimental: Observational cohort: RR/MDR-TB Participants receiving XBOS for 4 months (17 Weeks) -


Treatment: Drugs: Delamanid, Bedaquiline, OPC-167832, and Sutezolid (DBOS)
D- 300 milligram (mg) once daily (QD) for treatment duration; B- 400 mg QD for 2 weeks, 200 mg thrice weekly for remaining treatment weeks; O- 30 mg QD for treatment duration and S- 1200 mg QD for treatment duration

Treatment: Drugs: Pretomanid, Bedaquiline, OPC-167832, and Sutezolid (PBOS)
P- 200 mg QD for treatment duration; B- 400 mg QD for 2 weeks, 200 mg thrice weekly for remaining treatment weeks; O- 30 mg QD for treatment duration and S- 1200 mg QD for treatment duration

Treatment: Drugs: Isoniazid, Rifampicin, Pyrazinamide, Ethambutol (HRZE)
Fixed dose combination (FDC) of 75 mg of isoniazid, 150 mg of rifampicin, 400 mg of pyrazinamide, and 275 mg of ethambutol (HRZE) (Standard of Care \[SOC\]). All the doses administered will be weight-based.

Treatment: Drugs: Pretomanid or Delamanid, Bedaquiline, OPC-167832, and Sutezolid (XBOS)
X - Pretomanid 200 mg QD for treatment duration OR Delamanid 300 mg QD for treatment duration; B - 400 mg QD for 2 weeks, 200 mg thrice weekly for remaining treatment weeks; O- 30 mg QD for treatment duration and S-1200 mg QD for treatment duration

Treatment: Drugs: Isoniazid and Rifampicin (HR)
Fixed dose combination (FDC) of 75 mg of isoniazid and 150 mg of rifampicin (HR) (Standard of Care \[SOC\]). All the doses administered will be weight-based.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Stage 1: Percentage of participants with DS-TB reporting severe Adverse events (AEs) (= Grade 3) and/or Serious adverse events (SAEs), by treatment group
Timepoint [1] 0 0
Up to Week 19 for DBOS and PBOS; up to Week 28 for 2HRZE/4HR
Primary outcome [2] 0 0
Stage 1: Percentage of participants with pulmonary DS-TB with unfavorable outcome, by treatment group
Timepoint [2] 0 0
At Week 17 for DBOS and PBOS; at Week 26 for 2HRZE/4HR
Primary outcome [3] 0 0
Stage 2: Percentage of participants with DS-TB reporting severe AEs (= Grade 3) and/or SAEs, by treatment group
Timepoint [3] 0 0
Up to Week 19 for XBOS treatment groups; up to Week 28 for 2HRZE/4HR
Primary outcome [4] 0 0
Stage 2: Percentage of participants with pulmonary DS-TB reporting unfavorable outcome, by treatment group
Timepoint [4] 0 0
At 12 months post-randomization
Secondary outcome [1] 0 0
Stage 1: Percentage of participants reporting all-cause trial treatment discontinuation, by treatment group
Timepoint [1] 0 0
Through 12 months post-randomization
Secondary outcome [2] 0 0
Stage 1: Percentage of participants reporting severe AEs (= Grade 3) and/or SAEs, by treatment group
Timepoint [2] 0 0
Through 12 months post-randomization
Secondary outcome [3] 0 0
Stage 1: Percentage of participants with pulmonary DS-TB and Human immunodeficiency virus (HIV) co-infection reporting severe AEs (= Grade 3) and/or SAEs, by treatment group
Timepoint [3] 0 0
Up to Week 19 for DBOS and PBOS; up to Week 28 for 2HRZE/4HR
Secondary outcome [4] 0 0
Stage 1: Percentage of participants with pulmonary DS-TB and HIV co-infection reporting severe AEs (= Grade 3) and/or SAEs, by treatment group
Timepoint [4] 0 0
Through 12 months post-randomization
Secondary outcome [5] 0 0
Stage 1: Percentage of participants with pulmonary DS-TB and HIV co-infection reporting all-cause trial treatment discontinuation, by treatment group
Timepoint [5] 0 0
Through 12 months post-randomization
Secondary outcome [6] 0 0
Stage 1: Percentage of participants with pulmonary DS-TB reporting unfavorable outcome, by treatment group
Timepoint [6] 0 0
At 12 months post-randomization
Secondary outcome [7] 0 0
Stage 1: Percentage of participants with DS-TB and HIV co-infection reporting unfavorable outcome, by treatment group
Timepoint [7] 0 0
At Week 17 for DBOS and PBOS; at Week 26 for 2HRZE/4HR
Secondary outcome [8] 0 0
Stage 1: Percentage of participants reporting unfavorable outcome, by treatment group
Timepoint [8] 0 0
At 6 months post-randomization
Secondary outcome [9] 0 0
Stage 1: Time to sustained sputum culture conversion to negative for Mtb growth in Mycobacteria Growth Indicator Tube (MGIT) culture in participants receiving combination of DBOS and PBOS relative to 2HRZE/4HR
Timepoint [9] 0 0
Up to Week 28
Secondary outcome [10] 0 0
Stage 1: Mean change from Baseline in sputum MGIT culture time to detection (TTD) in participants receiving combination of DBOS and PBOS relative to 2HRZE/4HR
Timepoint [10] 0 0
Baseline and at Weeks 4, 8, 9, 13, and 17
Secondary outcome [11] 0 0
Stage 1: Percentage of participants with sustained sputum culture conversion in MGIT culture through Week 26, by treatment group
Timepoint [11] 0 0
Through Week 26 post-randomization
Secondary outcome [12] 0 0
Stage 1: Time to sustained sputum culture conversion to negative in solid culture, by treatment group
Timepoint [12] 0 0
Up to Week 19 for DBOS and PBOS; up to Week 28 for 2HRZE/4HR
Secondary outcome [13] 0 0
Stage 1: Percentage of participants with sustained sputum culture conversion in solid culture, by treatment group
Timepoint [13] 0 0
Up to Week 19 for DBOS and PBOS; up to Week 28 for 2HRZE/4HR
Secondary outcome [14] 0 0
Stage 1: Percentage of participants developing resistance against each drug
Timepoint [14] 0 0
Up to 12 months post-randomization
Secondary outcome [15] 0 0
Stage 1: Change from Baseline in minimum inhibitory concentration (MIC) for delamanid, pretomanid, bedaquiline, OPC-167832, and sutezolid drugs
Timepoint [15] 0 0
Up to 12 months post-randomization
Secondary outcome [16] 0 0
Stage 1: Geometric mean concentration of DBOS in participants with pulmonary DS-TB
Timepoint [16] 0 0
Pre-dose, post-dose at Weeks 1, 2, 4, 6, 9, 11, 13, 15, 17, 19, 21, 23, 26 and at Months 9, 12
Secondary outcome [17] 0 0
Stage 1: Geometric mean concentration of PBOS in participants with pulmonary DS-TB
Timepoint [17] 0 0
Pre-dose, post-dose at Weeks 1, 2, 4, 6, 9, 11, 13, 15, 17, 19, 21, 23, 26 and at Months 9, 12
Secondary outcome [18] 0 0
Stage 1: Geometric mean concentration of DBOS in participants with DS-TB and HIV co-infection
Timepoint [18] 0 0
Pre-dose, post-dose at Weeks 1, 2, 4, 6, 9, 11, 13, 15, 17, 19, 21, 23, 26 and at Months 9, 12
Secondary outcome [19] 0 0
Stage 1: Geometric mean concentration of PBOS in participants with DS-TB and HIV co-infection
Timepoint [19] 0 0
Pre-dose, post-dose at Weeks 1, 2, 4, 6, 9, 11, 13, 15, 17, 19, 21, 23, 26 and at Months 9, 12
Secondary outcome [20] 0 0
Stage 1: Geometric coefficient of variation of DBOS in participants with pulmonary DS-TB
Timepoint [20] 0 0
Pre-dose, post-dose at Weeks 1, 2, 4, 6, 9, 11, 13, 15, 17, 19, 21, 23, 26 and at Months 9, 12
Secondary outcome [21] 0 0
Stage 1: Geometric coefficient of variation of PBOS in participants with pulmonary DS-TB
Timepoint [21] 0 0
Pre-dose, post-dose at Weeks 1, 2, 4, 6, 9, 11, 13, 15, 17, 19, 21, 23, 26 and at Months 9, 12
Secondary outcome [22] 0 0
Stage 1: Geometric coefficient of variation of DBOS in participants with DS-TB and HIV co-infection
Timepoint [22] 0 0
Pre-dose, post-dose at Weeks 1, 2, 4, 6, 9, 11, 13, 15, 17, 19, 21, 23, 26 and at Months 9, 12
Secondary outcome [23] 0 0
Stage 1: Geometric coefficient of variation of PBOS in participants with DS-TB and HIV co-infection
Timepoint [23] 0 0
Pre-dose, post-dose at Weeks 1, 2, 4, 6, 9, 11, 13, 15, 17, 19, 21, 23, 26 and at Months 9, 12
Secondary outcome [24] 0 0
Stage 2: Percentage of participants with DS-TB receiving XBOS reporting all-cause trial treatment discontinuation
Timepoint [24] 0 0
Week 9 through 17
Secondary outcome [25] 0 0
Stage 2: Percentage of participants with DS-TB receiving 2HRZE/4HR reporting all-cause trial treatment discontinuation
Timepoint [25] 0 0
Up to week 26
Secondary outcome [26] 0 0
Stage 2: Percentage of participants with DS-TB reporting Severe AEs (= Grade 3) and/or SAEs, by treatment group
Timepoint [26] 0 0
Through 12 months post-randomization
Secondary outcome [27] 0 0
Stage 2: Percentage of participants with pulmonary DS-TB and HIV co-infection reporting severe AEs (= Grade 3) and/or SAEs, by treatment group
Timepoint [27] 0 0
Up to Week 11, Week 13, Week 15, Week 17, and Week 19 for XBOS treatment groups; up to Week 28 for 2HRZE/4HR
Secondary outcome [28] 0 0
Stage 2: Percentage of participants with pulmonary DS-TB and HIV co-infection reporting severe AEs (= Grade 3) and/or SAEs, by treatment group
Timepoint [28] 0 0
Through 12 months post-randomization
Secondary outcome [29] 0 0
Stage 2: Percentage of participants with pulmonary DS-TB and HIV co-infection reporting all-cause trial treatment discontinuation, by treatment group
Timepoint [29] 0 0
Up to Week 9, Week 11, Week 13, Week 15, and Week 17 for XBOS treatment groups; up to Week 26 for 2HRZE/4HR
Secondary outcome [30] 0 0
Stage 2: Percentage of participants with RR/MDR-TB reporting severe AEs (= Grade 3) and/or SAEs in participants who receive XBOS for four months
Timepoint [30] 0 0
Up to 19 weeks
Secondary outcome [31] 0 0
Stage 2: Percentage of participants with RR/MDR-TB reporting severe AEs (= Grade 3) and/or SAEs in participants who receive XBOS for four months
Timepoint [31] 0 0
Through 12 months post-randomization
Secondary outcome [32] 0 0
Stage 2: Percentage of participants with RR/MDR-TB reporting all-cause trial treatment discontinuation in participants who receive XBOS for four months
Timepoint [32] 0 0
Up to 17 weeks
Secondary outcome [33] 0 0
Stage 2: Percentage of participants with pulmonary DS-TB reporting unfavorable outcome, by treatment group
Timepoint [33] 0 0
Week 9, Week 11, Week 13, Week 15, and Week 17 for XBOS treatment groups; at Week 26 for 2HRZE/4HR
Secondary outcome [34] 0 0
Stage 2: Percentage of participants with pulmonary DS-TB and HIV co-infection reporting unfavorable outcome, by treatment group
Timepoint [34] 0 0
Through 12 months post-randomization
Secondary outcome [35] 0 0
Stage 2: Percentage of participants reporting unfavorable outcome, by treatment group
Timepoint [35] 0 0
At 6 months post-treatment after randomized duration of treatment
Secondary outcome [36] 0 0
Stage 2: Time to sustained sputum culture conversion to negative for Mtb growth in MGIT culture in participants receiving combination of XBOS relative to 2HRZE/4HR
Timepoint [36] 0 0
Up to Week 28
Secondary outcome [37] 0 0
Stage 2: Mean change from Baseline in sputum MGIT culture TTD in participants receiving combination of XBOS relative to 2HRZE/4HR
Timepoint [37] 0 0
Baseline and at Weeks 4, 8, 9, 11, 13, 15, and 17
Secondary outcome [38] 0 0
Stage 2: Percentage of participants with sustained sputum culture conversion to negative at Week 8 and end of treatment, by treatment group
Timepoint [38] 0 0
At Week 8 for all treatment groups; at Week 9, Week 11, Week 13, Week 15, and Week 17 for all XBOS treatment groups; at Week 26 for 2HRZE/4HR
Secondary outcome [39] 0 0
Stage 2: Time to sustained sputum culture conversion to negative in solid culture in participants receiving combination of XBOS relative to 2HRZE/4HR
Timepoint [39] 0 0
Up to Week 28
Secondary outcome [40] 0 0
Stage 2: Percentage of participants with sustained sputum culture conversion in solid culture, by treatment group
Timepoint [40] 0 0
Up to Week 11, Week 13, Week 15, Week 17, and Week 19 for XBOS treatment groups; up to Week 28 for 2HRZE/4HR
Secondary outcome [41] 0 0
Stage 2: Percentage of participants with sustained sputum culture conversion to negative by each treatment group
Timepoint [41] 0 0
Up to Week 28
Secondary outcome [42] 0 0
Stage 2: Percentage of participants developing resistance against each drug
Timepoint [42] 0 0
Up to 12 months post-randomization
Secondary outcome [43] 0 0
Stage 2: Change from Baseline in MIC for delamanid, pretomanid, bedaquiline, OPC-167832, and sutezolid drugs
Timepoint [43] 0 0
Up to 12 months post-randomization
Secondary outcome [44] 0 0
Stage 2: Geometric mean concentration of XBOS in participants with pulmonary DS-TB and RR/MDR-TB
Timepoint [44] 0 0
Pre-dose, post-dose at Weeks 1, 2, 4, 6, 9, 11, 13, 15, 17, 19, 21, 23, 26 and at Months 9, 12
Secondary outcome [45] 0 0
Stage 2: Geometric mean concentration of XBOS in participants with DS-TB and HIV co-infection
Timepoint [45] 0 0
Pre-dose, post-dose at Weeks 1, 2, 4, 6, 9, 11, 13, 15, 17, 19, 21, 23, 26 and at Months 9, 12
Secondary outcome [46] 0 0
Stage 2: Geometric coefficient of variation of XBOS in participants with pulmonary DS-TB and RR/MDR-TB
Timepoint [46] 0 0
Pre-dose, post-dose at Weeks 1, 2, 4, 6, 9, 11, 13, 15, 17, 19, 21, 23, 26 and at Months 9, 12
Secondary outcome [47] 0 0
Stage 2: Geometric coefficient of variation of XBOS in participants with DS-TB and HIV co-infection
Timepoint [47] 0 0
Pre-dose, post-dose at Weeks 1, 2, 4, 6, 9, 11, 13, 15, 17, 19, 21, 23, 26 and at Months 9, 12

Eligibility
Key inclusion criteria
For Stage 1:

* Able to provide written, informed consent prior to initiation of any trial-related procedures or treatments, and able, in the opinion of the Investigator, to comply with all the requirements of the trial.
* Male or female participants between 18 and 65 years of age (inclusive) at the screening visit.
* Body weight =35.0 kilograms (kg) and body mass index (BMI) =16.0 at the screening visit.
* Newly diagnosed within the past 8 weeks prior to informed consent, untreated (=4 days of treatment), drug-susceptible pulmonary TB, as defined by all of the following:

1. Confirmation of Mtb infection: Mtb positivity on a molecular test (eg, Xpert Ultra, Hain Line probe assay [LPA]) conducted on a sputum specimen for trial screening.
2. Evidence of non-paucibacillary disease: =1+ sputum smear positivity for acid-fast bacilli using fluorescent microscopy, as defined by the International Union Against Tuberculosis and Lung Disease (IUATLD)/World Health Organization (WHO) scale, OR a Xpert Ultra semi-quantitative result of 'medium' or 'high' on the sputum specimen for trial screening.
3. Drug-susceptible TB: Isoniazid and rifampicin resistance not detected, as determined by a molecular test (eg, Hain LPA, Xpert Ultra, Xpert MTB/Extensively Drug Resistant [XDR]) conducted on a sputum specimen for trial screening.
4. Clinical signs and/or symptoms consistent with active TB in the opinion of the Investigator.
5. Chest radiograph consistent with active TB in the opinion of the Investigator. Note, the Investigator is permitted, but not required, to incorporate a radiologist's interpretation into their assessment of a participant's chest radiograph.
* Able to spontaneously produce sputum.
* Female participants of childbearing potential (FOCBP) must agree to use 2 approved methods of contraception with their male sexual partners or abstain from heterosexual intercourse throughout their participation in the trial.
* Male participants must agree to use an approved method of contraception with their female sexual partners of childbearing potential or abstain from heterosexual intercourse throughout their participation in the trial.

For Stage 2:

• Newly diagnosed within the past 8 weeks of informed consent, untreated (=4 days of treatment), drug-susceptible or rifampicin-/multi-drug resistant pulmonary TB, as defined by all of the following:

1. Confirmation of Mtb infection: Mtb positivity on a molecular test (eg, Xpert Ultra, Hain LPA) conducted on a screening sputum specimen.
2. Evidence of non-paucibacillary disease: =1+ sputum smear positivity for acid-fast bacilli using fluorescent microscopy, as defined on the IUATLD/WHO scale, OR Xpert Ultra semi-quantitative result of 'medium' or 'high' on the sputum specimen for trial screening.
3. Resistance pattern:

i. For DS TB arm, isoniazid and rifampicin resistance not detected on a molecular test (eg, Hain LPA, Xpert Ultra, Xpert MTB/XDR) conducted on a screening sputum specimen, OR

ii. For RR/MDR TB arm, either rifampicin resistance (RR TB) OR rifampicin and isoniazid resistance (MDR TB) detected on a molecular test (eg, Hain LPA, Xpert Ultra, Xpert MTB/XDR) conducted on a screening sputum specimen.

• Participants with RR or MDR TB must also have fluoroquinolone resistance not detected, as determined by a molecular test (eg, Hain LPA second line, Xpert MTB/XDR) performed on the sputum specimen for trial screening.

d) Clinical signs and/or symptoms consistent with active TB in the opinion of the Investigator.

e) Chest radiograph consistent with active TB in the opinion of the Investigator.

The other inclusion criteria remain the same for Stage 2.
Minimum age
18 Years
Maximum age
65 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Suspected or documented extra-thoracic TB. Confirmed or suspected lymph node TB is not considered exclusionary. The presence of a pleural effusion considered not clinically significant together with pulmonary TB is not exclusionary.
* Known, or suspected of having, resistance to a rifamycin, isoniazid, ethambutol, pyrazinamide, delamanid, pretomanid, bedaquiline, linezolid, tedizolid, or sutezolid either confirmed by the laboratory, or based on epidemiological history, such as a known source case with said resistance.
* Received any prior treatment for active Mtb disease (>4 days) within the past 1 year of informed consent.
* Received any treatment with a fluoroquinolone active against Mtb (ie, levofloxacin, moxifloxacin, ciprofloxacin) or an aminoglycoside for more than 14 days within the 3 months prior to informed consent even if the medication was given for a different indication than TB treatment.
* Any known prior exposure to delamanid, pretomanid, bedaquiline, OPC-167832, or any oxazolidinone (linezolid, tedizolid, delpazolid, or sutezolid).
* Evidence of an active clinically significant/uncontrolled metabolic, gastrointestinal, neurological (including peripheral neuropathy), psychiatric, endocrine (including uncontrolled diabetes), hematologic, ophthalmologic (particularly optic neuritis), or liver disease; active malignancy; or other medical co-morbidity considered significant enough by the Investigator that the participant should not enter the trial.
* Significant history of, or current clinically relevant cardiovascular disorder, such as heart failure, coronary artery disease, uncontrolled hypertension, arrhythmia, tachyarrhythmia, prolonged QT syndrome, or presence of symptom(s) strongly suggestive of such a problem, such as exertional chest pressure/pain or unexplained syncope.
* Significant history of, or current evidence of an active clinically significant/poorly controlled pulmonary disease, such as asthma, Chronic obstructive Pulmonary disease (COPD), silicosis, or lung fibrosis (other than TB), considered as severe by the Investigator. In particular, any underlying pulmonary condition that could significantly interfere with the assessment of X-ray images, interpretation of sputum findings, or otherwise compromise the participant's participation in the trial is exclusionary based on the Investigator's judgement. Clinically significant post-Coronavirus disease-2019 (COVID-19) pulmonary sequelae should be considered exclusionary.
* If HIV-infected, having any of the following present:

1. Not on antiretroviral treatment at time of screening or taking antiretroviral treatment for <3 months prior to screening, OR
2. Cluster of differentiation (CD)4+ T-cell count <200 cells/microliter (µL) during the screening period, OR
3. HIV viral load >200 copies/milliliter (mL) during the screening period, OR
4. Evidence of a currently active opportunistic malignancy or infection related to HIV other than TB that requires treatment with a prohibited concomitant medication (oral candidiasis is not exclusionary) OR
5. HIV-infected participants enrolling at a trial site in Peru will not be eligible due to the requirement for longer TB treatment courses than the standard 6-month HRZE regimen for patients with HIV/TB co-infection as per the Peruvian national TB treatment guidelines.
* If female, currently pregnant or breastfeeding, OR having a positive serum or urine pregnancy test during the screening period, OR planning to become pregnant within the 12-month period after the screening period.
* Current significant drug and/or alcohol abuse that is likely to result in poor adherence to trial requirements or that would pose a risk to the participant's wellbeing during the trial.
* Karnofsky Performance Status scale score at screening of <60.
* Having a disease or condition where the use of delamanid, pretomanid, bedaquiline, OPC-167832, sutezolid, rifampicin, isoniazid, pyrazinamide, or ethambutol is contraindicated.
* Positive Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Polymerase chain reaction (PCR) result on nasopharyngeal sample taken during screening. Prior history of COVID-19/SARS-CoV-2 infection is not exclusionary if SARS-CoV-2 PCR performed on screening sample is negative.
* Any of the following laboratory results during screening:

1. Estimated creatinine clearance <60 mL/minute
2. Alanine transaminase (ALT) or aspartate transaminase (AST) >2.5 × upper limit of normal of the clinical laboratory reference range
3. Total bilirubin >2x upper limit of normal of the clinical laboratory reference range, at screening
4. Hemoglobin <8.0 grams per deciliter (g/dL)
5. Platelet count <100 x 10^9/liter (L)
6. White blood cell count <2.0 x 10^9/L
7. Screening glycosylated hemoglobin (HbA1c) =10.0%
8. Positive hepatitis B surface antigen
9. Positive hepatitis C antibody.
* Moderate to severe substance use disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria (substances of concern may include cocaine, amphetamines, opiates, barbiturates, benzodiazepines, or alcohol).
* A clinically significant Electrocardiogram (ECG) abnormality at screening as confirmed by a central ECG reading service. Examples of such include, but are not limited to, second- or third-degree atrioventricular block, complete right bundle branch block, left bundle branch block, QRS duration =120 millisecond (msec), QT interval corrected using Fridericia's formula (QTcF) interval >450 msec in males or >470 msec in females, atrial fibrillation or flutter, supraventricular tachycardia, and ventricular tachycardia or multiple multifocal premature ventricular complexes. The following ECG findings are not considered clinically significant: sinus tachycardia, mild first-degree atrioventricular block (P-R interval <0.23 sec), right or left axis deviation, incomplete right bundle branch block, and isolated left anterior fascicular block (left anterior hemiblock) in young otherwise healthy participants.
* Participants receiving any of the prohibited medications within the specified periods or who would be likely to require prohibited concomitant therapy during the trial.
* History of having taken another investigational drug within 30 days preceding trial entry or participates in another clinical study during the duration of this trial.
* Prospective approvals of protocol deviations to enrollment criteria, also known as protocol waivers or exemptions, are not permitted.
* Participants with baseline culture results (defined as collected during screening period through up to Week 1) that are all negative for growth of Mtb will not be included in efficacy analyses. DS-TB participants whose baseline phenotypic DST results demonstrate resistance to isoniazid and/or rifampicin will not be included in efficacy analyses. Their treatment will be modified accordingly based on their resistance profile, relevant local/national guidelines, and the participant's interest to continue in the trial after discussion with the Investigator.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Phase
Phase 2
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
26/07/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
31/01/2025
Actual
Sample size
Target
514
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment outside Australia
Country [1] 0 0
Philippines
State/province [1] 0 0
Makati
Country [2] 0 0
Philippines
State/province [2] 0 0
Quezon City
Country [3] 0 0
Philippines
State/province [3] 0 0
Silang
Country [4] 0 0
South Africa
State/province [4] 0 0
Cape Town
Country [5] 0 0
South Africa
State/province [5] 0 0
Durban
Country [6] 0 0
South Africa
State/province [6] 0 0
East London
Country [7] 0 0
South Africa
State/province [7] 0 0
Johannesburg
Country [8] 0 0
South Africa
State/province [8] 0 0
Klerksdorp

Funding & Sponsors
Primary sponsor type
Other
Name
Bill & Melinda Gates Medical Research Institute
Address
Country
Other collaborator category [1] 0 0
Other
Name [1] 0 0
Global Alliance for TB Drug Development
Address [1] 0 0
Country [1] 0 0
Other collaborator category [2] 0 0
Commercial sector/industry
Name [2] 0 0
Janssen Pharmaceutica
Address [2] 0 0
Country [2] 0 0
Other collaborator category [3] 0 0
Commercial sector/industry
Name [3] 0 0
Otsuka Pharmaceutical Co., Ltd.
Address [3] 0 0
Country [3] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Gates MRI
Address 0 0
Bill & Melinda Gates Medical Research Institute
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
When will data be available (start and end dates)?
Available to whom?
Available for what types of analyses?
How or where can data be obtained?


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.


Results not provided in https://clinicaltrials.gov/study/NCT05971602